{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glomerular+Disease",
    "query": {
      "condition": "Glomerular Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 126,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glomerular+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:50:13.243Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06858319",
      "title": "Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Diseases",
        "Kidney Diseases, Chronic",
        "Urological Diseases",
        "Glomerulonephritis",
        "Glomerular Disease",
        "Glomerulonephritis, IGA",
        "Glomerulopathy",
        "Immunoglobulin Disease"
      ],
      "interventions": [
        {
          "name": "zigakibart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 220,
      "start_date": "2025-07-28",
      "completion_date": "2031-06-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-05-22T02:50:13.243Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Orlando, Florida • Clifton Park, New York + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Clifton Park",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Brentwood",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06858319"
    },
    {
      "nct_id": "NCT04572854",
      "title": "Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "C3G",
        "IC-MPGN",
        "Renal Transplant",
        "Complement 3 Glomerulopathy",
        "Complement 3 Glomerulopathy (C3G)",
        "Dense Deposit Disease (DDD)",
        "Membranoproliferative Glomerulonephritis",
        "Membranoproliferative Glomerulonephritis (MPGN)",
        "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)",
        "C3 Glomerulopathy",
        "C3 Glomerulonephritis",
        "Complement 3 Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-09-07",
      "completion_date": "2026-01-20",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T02:50:13.243Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04572854"
    },
    {
      "nct_id": "NCT00977977",
      "title": "Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nephrotic Syndrome",
        "Proteinuria",
        "Autoimmune Disease",
        "Glomerular Disease",
        "Membranous Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "Rituximab Infusion",
          "type": "DRUG"
        },
        {
          "name": "Oral Cyclosporine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-12-22",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-05-22T02:50:13.243Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00977977"
    },
    {
      "nct_id": "NCT04287985",
      "title": "Safety and Efficacy Study of VIS649 for IgA Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A Nephropathy",
        "Glomerular Disease",
        "IgAN"
      ],
      "interventions": [
        {
          "name": "Dose-Placebo",
          "type": "DRUG"
        },
        {
          "name": "Low Dose-VIS649",
          "type": "DRUG"
        },
        {
          "name": "Medium Dose-VIS649",
          "type": "DRUG"
        },
        {
          "name": "High Dose-VIS649",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2020-07-20",
      "completion_date": "2023-06-18",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T02:50:13.243Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04287985"
    },
    {
      "nct_id": "NCT04939116",
      "title": "Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glomerular Disease",
        "Proteinuria"
      ],
      "interventions": [
        {
          "name": "ANG-3070",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Angion Biomedica Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-12-24",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2022-03-23",
      "last_synced_at": "2026-05-22T02:50:13.243Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Northridge, California • Vacaville, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Vacaville",
          "state": "California"
        },
        {
          "city": "Lauderdale Lakes",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04939116"
    },
    {
      "nct_id": "NCT02795676",
      "title": "Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "PRX-102 (pegunigalsidase alfa)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "agalsidase beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protalix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 78,
      "start_date": "2016-06",
      "completion_date": "2022-07",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-05-22T02:50:13.243Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02795676"
    },
    {
      "nct_id": "NCT02229214",
      "title": "Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Qsymia",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VIVUS LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 51,
      "start_date": "2014-08",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2017-11-07",
      "last_synced_at": "2026-05-22T02:50:13.243Z",
      "location_count": 1,
      "location_summary": "Lakewood, Colorado",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02229214"
    },
    {
      "nct_id": "NCT00976495",
      "title": "Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Hydrochlorothiazide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 154,
      "start_date": "2009-10",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2017-03-08",
      "last_synced_at": "2026-05-22T02:50:13.243Z",
      "location_count": 9,
      "location_summary": "Anaheim, California • Lomita, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00976495"
    },
    {
      "nct_id": "NCT06983028",
      "title": "Atacicept in Multiple Glomerular Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "pMN",
        "IgAN",
        "Nephrotic Syndrome",
        "MCD",
        "FSGS"
      ],
      "interventions": [
        {
          "name": "Atacicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-07-07",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-05-22T02:50:13.243Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06983028"
    },
    {
      "nct_id": "NCT03380377",
      "title": "Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Antibody-mediated Rejection",
        "Kidney Transplant; Complications",
        "Transplant Glomerulopathy",
        "Transplant Glomerulopathy - Late Form",
        "Transplant Glomerulopathy - Early Form",
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanley Jordan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "15 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-02-21",
      "completion_date": "2024-04-16",
      "has_results": true,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-05-22T02:50:13.243Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380377"
    }
  ]
}